American consumers are still having a hard time finding Tylenol on some drugstore shelves, more than three years since manufacturing problems created a disruption in supply.
Class-action lawsuits make news for their big sums – last year, pharmaceutical giant Merck settled a suit over its heart drug Vioxx for $37-million – but a more prosaic challenge gets less attention.
